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Aims: Heart failure is a clinical syndrome characterized by subclinical systemic
inflammation and immune system activation associated with iron deficiency. No data
exist on the various activations of immune-mediated mechanisms of inflammation in
heart failure patients with reduced/preserved ejection fraction. We aimed to (1) investigate
possible differences in inflammatory parameters and oxidative stress, and (2) detect a
different iron status between groups.
Materials and Methods: We enrolled 50 consecutive Caucasian outpatients with
heart failure. All patients underwent echocardiographic measurements, laboratory
determinations, evaluation of iron status and Toll-like receptors, and NF-κB expression in
peripheral blood mononuclear cells, as well as pro-inflammatory cytokines. All statistical
calculations were made using SPSS for Mac version 21.0.
Results: Patients with reduced ejection fraction showed significantly lower hemoglobin
levels (12.3 ± 1.4 vs. 13.6 ± 1.4 g/dl), serum iron (61.4 ± 18.3 vs. 93.7 ± 33.7
mcg/dl), transferrin iron binding capacity (20.7 ± 8.4 vs. 31.1 ± 15.6 %), and e-GFR
values (78.1 ± 36.1 vs. 118.1 ± 33.9 ml/min/1.73 m2) in comparison to patients with
preserved ejection fraction, while unsaturated iron binding capacity (272.6 ± 74.9 vs.
221.7 ± 61.4 mcg/dl), hepcidin (4.61 ± 0.89 vs. 3.28 ± 0.69 ng/ml), and creatinine
(1.34 ± 0.55 vs. 1.03 ± 0.25 mg/dl) were significantly higher in the same group. When
considering inflammatory parameters, patients with reduced ejection fraction showed
significantly higher expression of both Toll-like receptors-2 (1.90 ± 0.97 vs. 1.25 ± 0.76
MFI) and Toll-like receptors-4 (4.54 ± 1.32 vs. 3.38 ± 1.62 MFI), respectively, as well
as a significantly higher activity of NF-κB (2.67 ± 0.60 vs. 1.07 ± 0.30). Furthermore,
pro-inflammatory cytokines, interleukin-1, and interleukin-6, was significantly higher in
patients with reduced ejection fraction, while the protective cytokine interleukin-10 was
significantly lower in the same group. Correlational analyses demonstrated a significant
and inverse relationship between left ventricular function and inflammatory parameters
in patients with reduced ejection fraction, as well as a direct correlation between ferritin
and inflammatory parameters.
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Conclusions: Our data demonstrate a different immune-mediated inflammatory
burden in heart failure patients with reduced or preserved ejection fraction, as well
as significant differences in iron status. These data contribute to further elucidate
pathophysiologic mechanisms leading to cardiac dysfunction.
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INTRODUCTION
Heart failure (HF) is a complex clinical syndrome, characterized
by impairment of both the cardiac structure and function leading
to left ventricle filling or ejection abnormalities. In addition,
HF is one of the most common causes of hospitalization
recurrence and death (1, 2). Recently, according to the value
of echocardiographic left ventricular ejection fraction (EF), HF
guidelines have identified three main forms of HF including: HF
with reduced EF (HF-rEF; EF≤40%), HF with preserved EF (HF-
pEF; EF ≥50%), and an intermediate form with an EF ranging
from 41 to 49% (1).
It is well established that HF patients, independent from
prevalent systolic or diastolic dysfunction, show increased
levels of pro-inflammatory cytokines, associated to adverse
clinical outcomes (3, 4). This inflammatory status, probably
driven by the coexistence of traditional cardiovascular (CV)
risk factors, is maintained by other mechanisms such as
immune system activation (3, 4). In addition, this chronic
subclinical systemic inflammatory status is associated with
iron deficiency (ID), even in absence of clinically evident
anemia (5, 6), which also contributes to HF progression and
associated mortality (7) (Figure 1). Randomized trials (8–10) of
intravenous ferric carboxymaltose in the treatment of ID in HF-
rEF patients demonstrated an improvement of symptoms, and
this therapeutic approach should be considered when treating ID
in this setting of patients, in order to alleviate symptoms.
The subclinical inflammation seen in HF patients is due to
the higher activation and expression of toll-like receptors (TLRs),
in particular TLR-2 and TLR-4 that, in turn, induces the gene
transcription of pro-inflammatory cytokines (11–13).
To our knowledge, at this time, no data exist on a different
activation of the immune-mediatedmechanisms of inflammation
in HF-rEF and HF-pEF patients. Thus, this study is aimed to: (1)
investigate possible differences in inflammatory parameters and
oxidative stress [evaluated by nuclear factor kB (NF-κB)] between
HF-rEF and HF-pEF patients, and (2) to detect a different iron
status in the two groups.
MATERIALS AND METHODS
In this study we enrolled 50 consecutive Caucasian outpatients,
34 males and 16 females with a mean age of 70.7± 10.7 years. HF
diagnosis was carried out according to the recent guidelines of the
European Society of Cardiology (6), considering the presence of
symptoms and/or signs, as well as echocardiographic parameters.
For HF-pEF echocardiographic parameters considered were
left ventricular (LV) EF ≥50 %, and evidence of LV diastolic
dysfunction. For HF-rEF echocardiographic parameters
considered were LV volumes, a LVEF of 40% or less, LV wall
thickness, functioning valves, and pulmonary hypertension.
Exclusion criteria were history of autoimmune diseases and
all the conditions associated with immune system activation,
hemochromatosis, and other conditions associated with iron
metabolism disorders, other forms of anemia different from
the sideropenic one, cardiac storage diseases, congenital
cardiomyopathies, myocarditis or dilated cardiomyopathy
myocarditis-related, malignancies, thyroid dysfunctions, liver
insufficiency, and administration of any drug interfering with
iron metabolism (iron supplementation, antibiotics, diuretics,
laxatives, fibrates, antacids, proton pump inhibitors, metformin,
biguanides, alcohol). NYHA classification was performed
according to current guidelines. The Ethical Committee
approved the protocol and informed written consent was
obtained from all participants. All the investigations were
performed in accordance with the principles of the Declaration
of Helsinki.
Echocardiographic Measurements
Tracings were taken 24–48 h after laboratory/clinical
determinations with patients in a partial left decubitus position,
using a VIVID-7 Pro ultrasound machine (GE Technologies,
Milwaukee, WI) with an annular phased array 2.5 MHz
transducer. Echocardiographic readings were taken in a random
order by the investigator, who had no knowledge of patients’
blood pressure (BP) and other clinical data. Only frames with
optimal visualization of cardiac structures were considered for
the reading. The mean values from at least five measurements
of each parameter for each patient were computed. Having the
same experienced sonographer (MS) performing all studies in
a dimly lit and quiet room, we optimized the measurements
reproducibility. In our laboratory, the coefficient of variations
was 3.35% for posterior wall (PW) thickness, 3.40% for inter-
ventricular septum (IVS) thickness, 1.30% for left ventricular
internal diameter (LVID), and 4.10% for left ventricular
mass (LVM). Tracings were recorded under two-dimensional
guidance, and M-mode measurements were taken at the tip of
the mitral valve or just below. Measurements of IVS, thickness,
PW thickness, and LVID were made at end-diastole and end-
systole. LVM was calculated using the Devereux equation (14)
and normalized by body surface area (i-LVM).
Measurements of EF were obtained by Simpson method. LV
diastolic function was evaluated according to diagnostic criteria
proposed by the American Society of Echocardiography (15).
Evaluation of left atrium volume, indexed for body surface
area (i-LAV), was obtained using the apical four-chamber and
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FIGURE 1 | In this illustration we schematically report the role of immune-mediated inflammation in iron status balance and the consequent effects on cardiac function
in heart failure. TLRs, toll-like receptors; TNF-α, tumor necrosis factor alpha; IL, interleukin.
two-chamber views. Pulsed Doppler trans-mitral flow velocity
profile was obtained from the apical four-chamber view, and
the sample volume was located at the tip of the mitral valve
leaflets. The following parameters were evaluated for diastolic
function: peak trans-valvular flow velocity in early diastole (E
wave), peak trans-valvular flow velocity in late diastole (A wave),
E-to-A ratio. Tricuspid regurgitant velocity (TRV), a useful
parameter to calculate systolic pulmonary arterial pressure (s-
PAP) and pulmonary vascular resistances (PVR), was derived
from the application of continuous wave Doppler along the
tricuspid regurgitant jet, using an apical four chamber projection
or a parasternal right ventricle (RV) inflow view for eccentric
regurgitant jet (16). s-PAP was calculated through the Bernoulli
equation: s-PAP = 4 (TRV)2+PVR. PVR were calculated using
the following formula: TRV peak/RVOT time velocity integral
(TVI) x10+0.16 (17).
Laboratory Determinations
All laboratory measurements were performed after fasting
for 12 h. Plasma glucose was determined immediately by the
glucose oxidation method [Glucose analyzer, Beckman Coulter,
Milan; intra-assay coefficient of variation (CV) 2.2%, inter-
assay CV 3.8%]. Total, low-density lipoprotein- (LDL), and
high-density lipoprotein- (HDL) cholesterol and triglyceride
concentrations were measured using enzymatic methods (Roche
Diagnostics GmbH, Mannheim, Germany). Uric acid and
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creatinine were measured using the Jaffe methodology. Values
of estimated glomerular filtration rate (eGFR) (ml/min/1.73 m2)
were calculated using the CKD-EPI equation. We preferred
this equation because it was developed from a much larger
cohort of patients, including both normal individuals and those
with chronic kidney disease. High-sensitivity C-reactive protein
(hs-CRP) levels were measured with an automated instrument
(Cardio- Phase hs-CRP, Siemens Healthcare). Fibrinogen is
dosed with a coagulation method on the instrument BCSXP. The
complete blood count was performed by flux cytometry.
Iron Status Evaluation
According to current recommendations (18), we defined ID
as: ferritin <100 µg/dl or ferritin of 100–299 µg/dl with a
transferrin saturation <20%; we adopted this definition because
pathogenetic mechanisms underlying iron abnormalities in HF
differ from other conditions of chronic inflammation. According
to this we also evaluated hepcidin concentration.
Serum iron was evaluated by a colorimetric test and direct
determination with ferro-zine; unsaturated iron binding capacity
(UIBC) and the percentage of saturated transferrin iron binding
capacity (TIBC) were measured using a colorimetric test
(Roche Diagnostics, Cobas 8000, Switzerland). Ferritin levels
were measured using an immunoturbidimetric assay (Roche
Diagnostics, Indianapolis, IN, USA). Transferrin values were
evaluated by nephelometric method.
Serum Hepcidin Evaluation
Serum hepcidin concentration was assessed with a specific
ELISA kit (Abbexa Human Hepcidin 25; Catalog No abx350221),
according to the manufacturer’s instructions. The standards and
samples are added to the wells, incubated and washed with wash
buffer. A biotin conjugated antibody specific to hepcidin 25
is used for detection. TMB substrate is used to visualize HRP
activity. TMB is catalyzed by HRP to produce a blue colored
product that changes into yellow after adding stop solution. O.D.
absorbance was measured spectrophotometrically at 450 nm in
a microplate reader, and the concentration of Hepc25 was then
calculated as the variation over the control. Intra and inter assay
precision values were<10%, respectively.
Evaluation of TLR2 and TLR4 Expression
Peripheral blood mononuclear cells (PBMCs) were isolated from
fresh peripheral samples by Ficoll gradient according to the
manufacturer’s instructions within 2 h after blood collection.
Isolated PBMCs were harvested and suspended in phosphate
buffered saline (PBS) for TLRs expression analysis by FACS, or
in hypotonic buffer and further processed to evaluate NF-κB
(p65) activity. Isolated PBMCs were labeled with an anti-CD14
antibody conjugated with phycoerythrin (PE) to identify the
monocytes within the isolated population and with an anti-TLR-
2 antibody conjugated with fluorescein isothiocyanate (FICT), or
with an anti-TLR-4 antibody conjugated with allophycocyanin
(APC). An ISO CD-14 (PE) non-specific antibody was employed
as a control isotype to exclude non-specific bonds. Samples were
acquired with a FACSCalibur (BD Biosciences) and analyzed by
Flow JO software (LLC). Themonocyte population was identified
by both forward (FSC) and side scatter (SSC). TLRs expression
was considered as the ratio of mean fluorescence intensity (MFI)
of the sample and MFI of the isotype control.
NF-κB(p65) Activity Assay
Successively, to evaluate NF-κB(p65) activity PBMCs were lysed
with a hypotonic buffer containing 10mMHepes, 0.1mM EDTA
and phosphatase inhibitors. Supernatants containing cytosolic
fractions were removed and pellets were resuspended in a nuclear
extraction buffer containing 10mM Hepes, 0.1mM EDTA,
1.5mM MgCl2, 420mM NaCl, and 10% glycerol. NF-κB activity
in nuclear lysates was then measured with NF-κB specific ELISA
assay (Cayman Chemical Company, Ann Arbor, MI, USA),
according to the manufacturer’s instructions. A positive control
(human p65 transcription factor NF-κB) was included in each
ELISA plate; samples were assessed in duplicate.
Pro-inflammatory Cytokines Evaluation
To assess cytokine levels, serum samples were loaded into a
biochip array containing specific primary antibodies (Cytokine
and Growth Factors Array, Randox Laboratories) and processed
according to the user manual. Briefly, biochips were incubated
for 1 h at 37◦C, washed and incubated for an additional hour with
the HRP-conjugated secondary antibody. Biochips were acquired
with the biochip reader Evidence Investigator (Randox Labs, UK)
and the “Cytokines Array I and High sensitivity” kit, Randox UK,
quantified with its dedicated software. The assaymeasuring range
was 0–250 pg/ml for IL-6; 0–900 pg/ml for IL-8; 0–400 pg/ml for
IL-10; 0–600 for tumor necrosis factor (TNF)-α, and 0–600 pg/ml
for monocyte chemoattractant protein (MCP)-1. Intra and inter
assay precision values were 7.3 and 12.9 %, respectively, for IL-6;
7.7 and 6.7% for IL-8; 7.8 and 5.2% for IL-10; 9.9% for TNF-α; 3
and 7.6% for MCP-1.
Statistical Analysis
Descriptive data are presented as the mean ± SD for normally
distributed variables, and binary data as percent frequency.
Distribution normality was assessed with the Shapiro–Wilk test.
Groups were compared using an unpaired t-test when clinical
and biological data were expressed as continuous variables and
the χ2 test for categorical variables. Correlational analyses were
performed using the Pearson’s test. Differences were assumed to
be significant at two-tailed P-values< 0.05. All calculations were
done with a standard statistical package (SPSS for Mac version
21.0, Chicago, IL, USA).
RESULTS
On the basis of their EF, patients were divided into HF-rEF
and HF-pEF groups. All patients were in the NYHA II-III
functional class.
In Table 1 we reported the anthropometric, biochemical, and
hemodynamic characteristics of the whole study population and
of the two groups separately. The mean NHYA functional class
was significantly different between the groups (2.9 ± 0.5 vs. 2.2
± 0.5 in the HF-rEF and in the HF-pEF group, respectively).
No differences between the groups were detected with regards
to age, plasma glucose levels, total cholesterol, LDL-cholesterol,
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TABLE 1 | Anthropometric, biochemical and hemodynamic characteristics of the
whole study population and of the two groups separately.
All
(n = 50)
HF-rEF
(n = 25)
HF-pEF
(n = 25)
P
Gender, m/f 41/9 21/4 20/5
Age, years 70.7 ± 10.7 70.2 ± 12.8 71.1 ± 8.3 0.439
NYHA class 2.6 ± 0.5 2.9 ± 0.5 2.2 ± 0.5 0.0001
Etiology
– Ischemic/hypertensive 26 12 14 0.829
– Valvular 6 3 3
– Cardiomyopathy/other 18 10 8
SBP, mmHg 124 ± 14 118 ± 15 129 ± 10 0.0037
DBP, mmHg 72 ± 8 68 ± 7 76 ± 6 0.0001
Glucose, mg/dl 120.8 ± 25.4 124.8 ± 30.6 116.7 ± 23.2 0.296
Cholesterol, mg/dl 132.8 ± 30.9 130.0 ± 27.9 135.7 ± 34.5 0.523
LDL-Cholesterol, mg/dl 69.6 ± 24.3 67.8 ± 20.1 71.5 ± 28.3 0.455
HDL-Cholesterol, mg/dl 44.1 ± 8.5 40.9 ± 8.1 47.2 ± 7.7 <0.0001
Triglyceride, mg/dl 118.3 ± 64.1 121.1 ± 44.5 115.3 + 33.8 0.606
White blood cells,
103/µl
7.12 ± 1.97 7.49 ± 2.10 6.73 ± 1.81 0.176
Red blood cells,
106/µl
4.75 ± 0.50 4.72 ± 0.51 4.78 ± 0.49 0.673
MCV, fl 84.2 ± 3.6 86.3 ± 3.1 82.0 ± 3.0 0.0001
Hemoglobin, g/dl 12.9 ± 1.5 12.3 ± 1.4 13.6 ± 1.4 0.001
Serum iron, mcg/dl 77.1 ± 38.2 61.4 ± 18.3 93.7 ± 33.7 0.0001
Ferritin, ng/ml 104.1 ± 30.5 100.2 ± 24.7 108.1 ± 36.1 0.371
Transferrin, g/l 2.76 ± 0.52 2.83 ± 0.64 2.68 ± 0.29 0.291
UIBC, mcg/dl 251.6 ± 73.1 272.6 ± 74.9 221.7 ± 61.4 0.011
Saturated TIBC, % 25.3 ± 13.1 20.7 ± 8.4 31.1 ± 15.6 0.005
Hepcidin, ng/ml 4.25 ± 1.30 4.61 ± 0.89 3.28 ± 0.69 0.0001
Creatinine, mg/dl 1.19 ± 0.45 1.34 ± 0.55 1.03 ± 0.25 0.013
e-GFR, ml/min/1.73 m2 97.5 ± 40.1 78.1 ± 36.1 118.1 ± 33.9 0.0002
Uric acid, mg/dl 6.4 ± 1.7 6.8 ± 1.7 5.7 ± 1.1 0.009
DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; MCV, mean
corpuscular volume; SBP, systolic blood pressure; TIBC, transferrin iron binding capacity;
UIBC, unsaturated iron binding capacity.
and triglycerides, while both systolic and diastolic BP values
were significantly higher in the HF-pEF group. HF-rEF patients
showed higher creatinine and uric acid levels and lower e-GFR
and HDL-cholesterol values. No differences were observed in
the red blood cell counts between the groups, while a small, but
significant, difference was observed in hemoglobin levels (12.3
± 1.4 vs. 13.6 ± 1.4 g/dl, in the HF-rEF and in the HF-pEF
group, respectively). Clinically relevant, despite similar ferritin
and transferrin levels between groups, HF-rEF patients showed
a significant reduction in iron values and saturated transferrin
iron binding capacity (TIBC) percentage, and higher values of
unsaturated iron binding capacity (UIBC) and hepcidin levels.
In Table 2 we reported the inflammatory parameters of the
whole study population and of the two groups separately. HF-
rEF patients showed a significant increased expression of both
TLR-2 and TLR-4 (Figure 2), as well as significantly raised IL-6,
TABLE 2 | Inflammatory parameters of the whole study population and of the two
groups separately.
All
(n = 50)
HF-rEF
(n = 25)
HF-pEF
(n = 25)
P
TLR2, MFI 1.58 ± 0.92 1.90 ± 0.97 1.25 ± 0.76 0.011
TLR4, MFI 3.98 ± 1.56 4.54 ± 1.32 3.38 ± 1.62 0.007
NF-κB 1.80 ± 0.93 2.67 ± 0.60 1.07 ± 0.30 0.0001
IL-6, pg/ml 10.6 ± 7.5 15.4 ± 7.7 6.0 ± 2.8 0.0001
IL-8, pg/ml 20.6 + 10.1 22.4 + 12.8 18.6 + 6.2 NS
IL-10, pg/ml 1.8 ± 1.4 1.4 ± 0.9 2.3 ± 1.7 0.023
MCP-1, pg/ml 451.2 ± 98.1 478.8 ± 81.7 401.4 ± 94.6 0.003
TNF-α, pg/ml 3.5 ± 0.9 3.5 ± 1.2 3.5 ± 0.7 NS
hs-CRP, mg/L 4.0 ± 2.9 5.9 ± 2.6 1.9 ± 1.2 0.0001
Fibrinogen, mg/dl 316.0 ± 73 336 ± 78 285 ± 57 0.011
hsCRP, High-sensitivity C-reactive protein; IL, Interleukin; MCP1, Monocyte
Chemoattractant Protein-1; NF-κB, nuclear factor κB; TLR2, toll-like receptor-2;
TLR4, toll-like receptor-4; TNF-α, Tumor necrosis factor alpha.
FIGURE 2 | Levels of expression of TLR2 and TLR4 in PBMCs in patients with reduced ejection fraction (A) and preserved ejection fraction (B). As evident, (A) shows
a higher expression of TLRs, in particular of TLR4. FL4-H, TLR4; FL1-H, TLR2; TLRs, toll-like receptors.
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FIGURE 3 | This figure graphically describes inflammatory parameter differences between the HF-rEF and HF-pEF groups. For some parameters the values are
expressed as ×10 or ×100, as indicated. Comparisons between groups were made using a student’s t-test. N = 50 for each study group. For Elisa assays samples
were tested in duplicate. hsCRP, high-sensitivity C-reactive protein; IL, interleukin; MCP1, monocyte chemoattractant protein-1; NF-κB, nuclear factor kB; TLR,
toll-like receptor; TNF-α, tumor necrosis factor alpha.
TABLE 3 | Echocardiographic parameters of the whole study population and of
the two groups separately.
All
(n = 50)
HF-rEF
(n = 25)
HF-pEF
(n = 25)
P
EF, % 41.4 ± 7.8 35.3 ± 3.7 54.1 ± 5.2 0.0001
i-LVM, g/m2 150.5 ± 26.1 164.8 ± 21.3 138 ± 23.1 0.0001
EDV/BSA, ml/m2 89.4 ± 24.4 103.6 ± 22.3 74.4 ± 15.6 0.0001
ESV/BSA, ml/m2 47.6 ± 17.6 63.1 ± 12.3 35.8 ± 10.7 0.0001
i-LAV, ml/m2 51.5 ± 13.5 55.4 ± 11.3 47.4 ± 14.3 0.033
E/A 0.9 ± 0.3 1 ± 0.4 0.8 ± 0.1 0.019
E, m/s 0.9 ± 0.3 1.1 ± 0.3 0.9 ± 0.2 0.0001
E/e’ 19.5 ± 5.4 18.5 ± 6.8 20.6 ± 3.1 0.166
s-PAP, mmHg 38.5 ± 10.4 41.4 ± 8.7 35.5 ± 11.1 0.042
TAPSe, mm 18.3 ± 3.1 18.1 ± 3.3 18.5 ± 2.6 0.636
BSA, body surface area; d-LVID, diastolic left ventricular internal diameter; EDV, end-
diastolic volume; EF, ejection fraction; ESV, end-systolic volume; i-LAV, indexed left
atrium volume; i-LVM, indexed left ventricular mass; s-LVID, systolic left ventricular
internal diameter; s-PAP, systolic pulmonary arterial pressure; TAPSe, tricuspid annular
plane excursion.
MCP-1, fibrinogen, and hs-CRP values. Notably, even if without
statistically significant differences between groups, IL-8 levels
resulted beyond the range of normality in both HF-rEF and
HF-pEF patients. On the contrary, we detected significantly
lower values of IL-10 in the HF-rEF group. NF-κB levels were
significantly higher in the HF-rEF group.
In Figure 3 we graphically reported differences between
groups in inflammatory parameters.
Table 3 describes the echocardiographic characteristics of
the whole study population and of the two groups separately.
As expected, EF was significantly lower in the HF-rEF group,
while i-MVS, d-LVID, s-LVID, LA diameter, i-LAV, E/A ratio,
and s-PAP resulted significantly higher in the same group.
Similarly, the right ventricular function parameters such as the
TAPSe and TAPSe/s-PAP ratio was also significantly impaired in
the HF-rEF.
In Table 4we reported the correlational analyses between iron
status and markers of inflammation and LVEF, hepcidin and
markers of inflammation, ferritin and markers of inflammation,
and iron status. When considering the correlation between LVEF
and iron status, we found a significant and direct correlation
with hemoglobin and serum iron in the whole study population
and in the HF-rEF group, while in the HF-pEF group the only
significant direct correlation was found with serum iron. A
significant inverse relationship was found between LVEF and
both IL-6 and hs-CRP in the whole study population and in
HF-rEF patients; furthermore, in this group we also found an
inverse relationship between LVEF and ferritin. The correlational
analysis between hepcidin and different parameters showed a
significant and direct correlation between IL-6, and TLR4 in
the whole study population and in the HF-rEF group, while
TLR2 was significantly correlated to hepcidin only in the whole
study population. No significant correlations were found for any
of the tested parameters in the HF-pEF group. Of note, the
correlational analysis between ferritin and different inflammatory
and iron status parameters, showed an inverse relationship with
both serum iron and hemoglobin, and a direct relationship with
IL-6 in the HF-rEF group, thus confirming that, in this group,
ferritin levels correlate best with inflammatory parameters rather
than with iron status.
DISCUSSION
There is convincing evidence that inflammation is associated
with an increased CV risk, independent of traditional risk
factors, even if clinical trials designed to test the efficacy of
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TABLE 4 | Correlational analyses between different parameters in the whole study
population and in the two groups separately.
All HF-rEF HF-pEF
R/P R/P R/P
LVEF and…
Hemoglobin 0.573/0.0001 0.414/0.020 −0.112/0.298
Iron 0.643/0.0001 0.645/0.0001 0.456/0.011
Ferritin 0.043/0.384 −0.594/0.001 0.031/0.443
IL-6 −0.793/0.0001 −0.382/0.030 −0.088/0.337
hs-CRP −0.772/0.0001 −0.586/0.001 0.075/0.361
Hepcidin and…
IL-6 0.558/<0.0001 0.398/0.024 0.094/0.377
TLR2 0.244/0.044 0.084/0.345 −0.018/0.466
TLR4 0.346/0.007 0.385/0.029 −0.095/0.326
Ferritin 0.119/0.205 0.229/0.136 0.240/0.124
Ferritin and…
Serum iron −0.018/ 0.450 −0.413/0.020 −0.022/0.458
Hemoglobin −0.137/0.171 −0.451/0.012 0.176/0.200
Transferrin −0.200/0.082 −0.056/0.395 −0.418/0.019
Saturated TIBC % 0.245/0.043 0.216/0.150 0.194/0.177
UIBC −0.245/0.472 −0.048/0.409 −0.377/0.032
IL-6 0.010/0.433 0.343/ 0.047 0.176/0.200
TLR2 0.024/0.433 0.164/ 0.217 0.039/0.426
TLR4 0.099/0.247 0.188/0.184 0.185/0.187
MCP-1 0.125/0.193 −0.191/0.180 0.446/0.013
IL-8 −0.036/0.402 0.140 /0.253 −0.210/0.157
TNFα −0.092/0.263 −0.042/0.422 −0.178/0.197
hs- CRP −0.099/0.248 0.100/0.317 −0.099/0.320
NF-κB −0.012/0.186 0.065/0.378 0.070/0.370
hs-CRP, High-sensitivity C-reactive protein; IL, Interleukin; LVEF, left ventricular ejection
fraction; MCP1:Monocyte Chemoattractant Protein-1; NF-κB, nuclear factor kB; TIBC,
transferrin iron binding capacity; TLR2, toll-like receptor-2; TLR4, toll-like receptor-4;
TNF-α, Tumor necrosis factor alpha; UIBC, unsaturated iron binding capacity.
anti-inflammatory therapy in the reduction of CV outcomes
gave conflicting results (19, 20). Even if some inflammatory
factors have been found to be elevated in failing patients,
the relationship between inflammation and HF still remains
to be completely elucidated. It is well demonstrated that
one of the putative pathogenetic underlying mechanisms of
this inflammatory status is recognized as the activation of
the immune system, both innate and adaptive (11, 21–24).
Of interest, some evidence showed that HF functional class
deterioration is related to an increase of some of these
inflammatory factors (23). In keeping with this, our study
demonstrates, for the first time, different immune-mediated
mechanisms of inflammation in HF patients with reduced or
preserved EF. In fact, we observed a significant increase of pro-
inflammatory cytokines and a parallel decrease of the protective
cytokine IL-10 in HF-rEF patients, reflecting a consensual
increased activation of TLRs. Our data are confirmatory of
previously published evidence demonstrating an impairment
in left ventricular function attributable to chronic TLR-2 and
TLR-4 chronic activation (11, 21–25). Obviously, these findings
reflect the dissimilar morphological and functional cardiac
impairment characterizing the two different forms of HF, as a
consequence of both dissimilar TLRs expression and oxidative
stress levels detected.
Moreover, inflammatory burden, per se, causes activation
of the transcriptional factor NF-κB that promotes the
overexpression of some proinflammatory cytokines, as
observed in our population, initiating a vicious cycle that,
if not interrupted, leads to cardiac end-stage disease. In fact, our
patients with reduced EF showed almost doubled values of NF-
κB. It is important to remark that, even if not investigated in our
study, proinflammatory mediators and oxidative stress induce
both dysfunctional mitochondrial autophagy and fibroblast
activation and proliferation with increased myocardial fibrosis,
which contributes to the progression of cardiac dysfunction
(23). It is worth noting that in the HF-rEF group, we observed
a significant increase of MCP-1, which is involved in early
post-myocardial infarction ventricular remodeling (21).
Another relevant result of this study is the different iron
statuses, observed for the first time, in patients with HF-rEF
and HR-pEF, respectively. Particularly, we documented that
HF-rEF patients have a significant reduction in serum iron
concentration, even if in the normal range, and a saturated TIBC
percentage, while UIBC was significantly higher, in absence of
overt anemia. The underlying pathogenetic mechanism may be
recognized in the different hepcidin biological activities exerted
in HF-rEF and HR-pEF patients. In fact, of clinical relevance,
we found increased hepcidin levels in HF-rEF that, probably,
induces a higher inhibition of duodenal iron absorption and
its mobilization from storage sites. It is well established that
hepcidin levels increase under an inflammatory stimulus, as
also documented in our study on the increase of some pro-
inflammatory cytokines. As a consequence of this inflammatory
activation, in the HF-rEF subjects we also observed a significant
increase in both hs-CRP and fibrinogen levels that are acute phase
response inflammatory proteins, and that are routinely available
in clinical practice. Furthermore, we found significantly reduced
hemoglobin concentrations in the HF-rEF group; this finding
may be attributable to several causes, such as hemodilution, iron
deficiency, or both.
In accordance with Van Linthout (26), our findings do
not allow establishing if inflammation has a causative or
a consequential role in HF; in fact, inflammation and
HF are strongly associated, activating some reverberant
circuits that reinforce each other. In keeping with this,
HF-associated comorbidities such as hypertension, chronic
obstructive pulmonary disease, type-2 diabetes mellitus, obesity,
atherosclerosis etc., are all characterized by mild inflammation
and increased oxidative stress (27, 28). Even if this inflammation
starts with traditional CV risk factors, it is important to
underline that this inflammatory burden is also associated with
the activation of some neurohormonal systems, such as the
renin-angiotensin-aldosterone system (29). This activation, in
turn, induces an increase in renal sodium and water reabsorption
promoting blood volume expansion, and an increase of both
cardiac post-load and cardiac work; in addition, the associated
increased aortic impedance and peripheral vascular resistances
also negatively impact cardiac function deterioration.
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Consistent with this evidence, pharmacological treatment of
HF continuously evolves in order to improve both survival
and quality of life. In fact, a one-size-fits-all approach may not
be appropriate for all patients with HF, and novel drugs have
been proposed for HF treatment. Among these, evidence has
demonstrated that intravenous iron supplementation in HF-rEF
patients with absolute or relative ID, with or without anemia,
is capable of improving cardiac function (8–10). These results
confirm the detrimental effect of ID on cardiac contractility of
failing patients, particularly for those with HF-rEF, probably as
a consequence of mitochondrial impairment that may further
promote cardiomyocytes dysfunction (30–33). However, even
if our HF-pEF patients did not exhibit ID, they already have
an inflammatory burden that, if not recognized and treated
early, could accelerate disease progression toward HF-rEF. The
effects of iron supplementation on the innate immunity-driven
inflammatory cascade have not yet been fully elucidated, nor does
our data contribute to reaching a possible explanation. For this
reason, further investigations are needed.
In conclusion, our data contribute to further elucidate
pathophysiologic mechanisms leading to cardiac dysfunction,
and consequently consent to hypothesize new therapeutic targets
for congestive HF.
Study Limitations
Our study has some limitations. First, due to the small sample
size, our findings need to be confirmed in wider studies. Related
to this point, our patients were very heterogeneous in terms
of HF etiology; this can be regarded a limitation since the
underlying causes of inflammation are not similar, but can also
be regarded a strength because our population is representative
of a real-life setting. Second, we evaluated neither intracellular
iron nor atrial natriuretic peptides, that can potentially add
important information. Finally, since we did not administer iron
supplementation in patients with ID, we do not know the effects
of iron therapy on both inflammatory parameters and cardiac
function in our study population.
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